SCHEMBL3390675

SCHEMBL3390675

FC(F)(F)c1ccc(-c2ccc(CBr)cc2)nc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 2/20 0.51
CYP11B1 P15538 1/20 0.46
CYP11B2 P19099 1/20 0.46
MAOB P27338 2/20 0.46
KDM1A O60341 2/20 0.46
PPARA Q07869 2/20 0.42
NPSR1 Q6W5P4 2/20 0.40
LTA4H P09960 1/20 0.40
KDM4E B2RXH2 1/20 0.39
NPC1 O15118 1/20 0.39
NFKB1 P19838 1/20 0.39
MAPK1 P28482 1/20 0.39
RAB9A P51151 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
GCK P35557 1/20 0.39
GCKR Q14397 1/20 0.39
P2RX7 Q99572 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30767576 1.00 KIF11 (0.51) KIF11CYP11B1CYP11B2MAOBKDM1A
SCHEMBL31375486 0.87 RAB9A (0.40) KIF11CYP11B1CYP11B2MAOBKDM1A
SCHEMBL27344645 0.86 KIF11 (0.63) KIF11CYP11B1CYP11B2MAOBKDM1A
SCHEMBL14037163 0.85 KIF11 (0.52) KIF11CYP11B1CYP11B2MAOBKDM1A
SCHEMBL29690424 0.84 KIF11 (0.61) KIF11CYP11B1CYP11B2MAOBKDM1A
SCHEMBL28530523 0.84 KIF11 (0.61) KIF11CYP11B1CYP11B2MAOBKDM1A
SCHEMBL2269528 0.83 KIF11 (0.51) KIF11CYP11B1CYP11B2MAOBKDM1A
SCHEMBL3387516 0.83 KIF11 (0.51) KIF11CYP11B1CYP11B2MAOBKDM1A
SCHEMBL8239616 0.83 KIF11 (0.51) KIF11CYP11B1CYP11B2MAOBKDM1A
SCHEMBL30462004 0.83 KIF11 (0.51) KIF11CYP11B1CYP11B2MAOBKDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568960-B1 BICYCLIC TETRAHYDROAZEPINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2026-04-29 EP disclosed
US-20250236614-A1 BICYCLIC TETRAHYDROAZEPINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2025-07-24 US disclosed
EP-4568959-A1 BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2025-06-18 EP disclosed
WO-2024033458-A1 BICYCLIC TETRAHYDROAZEPINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2024-02-15 WO disclosed
WO-2024033389-A1 BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2024-02-15 WO disclosed
US-20100298343-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. 2010-11-25 US disclosed
US-20100298343-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. 2010-11-25 US disclosed
US-20100298343-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. 2010-11-25 US disclosed
EP-2207547-A2 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS Amira Pharmaceuticals, Inc. (US) 2010-07-21 EP disclosed
WO-2009071504-A1 2,6-DISUBSTITUTED PYRIDINES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed
WO-2009045700-A2 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2009-04-09 WO disclosed
US-20070225285-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2007-09-27 US disclosed
US-20070225285-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2007-09-27 US disclosed
US-20070225285-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2007-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225285-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS ALOX5, ALOX15B, ALOX15 KIF11 4735/4885CYP11B1 1038/4885CYP11B2 1070/4885
US-20250236614-A1 BICYCLIC TETRAHYDROAZEPINE DERIVATIVES GRIN2C, CNR1, CNR2 KIF11 2058/4885CYP11B1 147/4885CYP11B2 137/4885
US-20100298343-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS ALOX5, ALOX15B, ALOX15 KIF11 4735/4885CYP11B1 1038/4885CYP11B2 1070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.